RemeGen Co., Ltd. (HKG:9995)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
88.80
+2.60 (3.02%)
At close: Mar 13, 2026
Market Cap63.05B +354.0%
Revenue (ttm)3.62B +89.4%
Net Income788.45M
EPS1.44
Shares Out556.51M
PE Ratio61.86
Forward PE41.56
Dividendn/a
Ex-Dividend Daten/a
Volume4,116,545
Average Volume3,440,156
Open85.65
Previous Close86.20
Day's Range83.95 - 90.60
52-Week Range15.50 - 126.60
Beta0.72
RSI58.42
Earnings DateMar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3,070
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9995
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements